SS
ALGS icon

SBI Securities’s Aligos Therapeutics ALGS Stock Holding History

SBI Securities’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$727 Buy
126
+100
+385% +$618 ﹤0.01% 2912
2026
Q1 		$193 Hold
26
– – ﹤0.01% 3231
2025
Q4 		$242 Hold
26
– – ﹤0.01% 3150
2025
Q3 		$255 Hold
26
– – ﹤0.01% 3237
2025
Q2 		$187 Buy
26
+10
+63% +$60 ﹤0.01% 3337
2025
Q1 		$132 Sell
16
-155
-91% -$3.4K ﹤0.01% 3358
2024
Q4 		$6.81K Buy
+171
New +$3.3K ﹤0.01% 1800

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SBI Securities's ALGS Position: Q2 2026 in Review

SBI Securities increased its Aligos Therapeutics (ALGS) stake by 385% in Q2 2026, buying an estimated $618 and bringing the position to 126 shares worth $727. The position accounts for ﹤0.01% of the portfolio, ranked #2912.

SBI Securities first reported a position in ALGS in Q4 2024 and has held it in 7 quarters since. The position peaked at $6.81K in Q4 2024. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • SBI Securities held 126 shares of Aligos Therapeutics worth $727 as of Q2 2026.
  • SBI Securities bought 100 Aligos Therapeutics shares in Q2 2026, an estimated $618.
  • Aligos Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2912 holding.
  • SBI Securities first reported a position in Aligos Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Aligos Therapeutics position peaked at $6.81K in Q4 2024.
  • 31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.